Do you want to link to this External Website and leave Amgen.nl?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Netherlands takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.


Wilt u deze Externe Website bezoeken en Amgen.nl verlaten?

U verlaat nu de website van Amgen Nederland. Amgen Nederland draagt geen verantwoordelijkheid voor, en oefent geen controle uit, over de organisaties, meningen or juistheid van de informatie van deze server of website.

BiTE® Immuno-Oncology Platform

BiTE® Immuno-Oncology Platform: The Next Generation of Cancer Treatment

More than 30 years ago, researchers discovered that the body's own immune system is capable of curing certain types of cancer itself under certain conditions. This potential is being exploited in a targeted manner in the context of new types of immune therapies. The strongest weapon in this regard is certain defense cells of the immune system, the so-called T-cells.

T-cells fight off intruders such as bacteria and viruses in the body. In this way, they help to prevent and cure diseases. In addition, under certain circumstances, T cells can recognize and destroy cancer cells that are produced naturally in the body.

Malignant cancer cells very often develop mechanisms by which they can suppress an immune response or remain undetected by the immune system. To close this loophole, our team at Amgen Research (Munich) GmbH has developed the "Bispecific T-cell Engager" BiTE® antibody constructs. Equipped with two different binding sites, BiTE® antibody constructs act as bridge molecules between certain defense cells of the body's own immune system, the T-cells, and cancer cells by binding to both cell types simultaneously. By binding to both cell types simultaneously, T cells are able to recognize and destroy previously unrecognized cancer cells.

In this 2-minute video the working mechanism of BiTE® is further explained: